Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 10,000 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 10,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the sale, the senior vice president owned 326,918 shares of the company's stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Rhonda Farnum also recently made the following trade(s):

• On Monday, July 14th, Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00.
• On Monday, June 2nd, Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock. The stock was sold at an average price of $11.00, for a total value of $264,000.00.
• On Monday, April 21st, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00.

Theravance Biopharma Stock Down 3.2%

Shares of TBPH stock traded down $0.37 during trading hours on Friday, hitting $11.25. 144,416 shares of the company were exchanged, compared to its average volume of 257,811. The firm has a fifty day moving average of $10.47 and a 200 day moving average of $9.67. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.88. The firm has a market cap of $562.50 million, a PE ratio of -9.53 and a beta of -0.02.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. The company had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Ballentine Partners LLC raised its holdings in shares of Theravance Biopharma by 9.3% in the 2nd quarter. Ballentine Partners LLC now owns 14,315 shares of the biopharmaceutical company's stock worth $158,000 after purchasing an additional 1,221 shares during the period. Assenagon Asset Management S.A. purchased a new position in Theravance Biopharma in the second quarter valued at approximately $264,000. Rhumbline Advisers raised its holdings in Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after buying an additional 2,293 shares during the period. Acadian Asset Management LLC grew its stake in Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after buying an additional 174,451 shares during the period. Finally, Jane Street Group LLC increased its position in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after acquiring an additional 88,540 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TBPH. Wall Street Zen lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. BTIG Research boosted their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Finally, Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a research report on Tuesday, June 17th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Theravance Biopharma currently has an average rating of "Moderate Buy" and a consensus target price of $16.60.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.